aim
present
studi
formul
poli
lactidecoglycolid
plga
nanoparticl
load
acid
gla
appropri
physicochem
properti
antimicrobi
activ
gla
load
plga
nanoparticl
prepar
differ
drug
polym
ratio
aceton
content
sonic
time
antibacteri
activ
develop
nanoparticl
examin
differ
gramneg
gramposit
bacteria
antibacteri
effect
studi
use
serial
dilut
techniqu
determin
minimum
inhibitori
concentr
nanoparticl
result
demonstr
physicochem
properti
nanoparticl
affect
mention
paramet
nanoscal
size
particl
rang
nm
achiev
highest
encapsul
effici
obtain
ratio
drug
polym
zeta
potenti
develop
nanoparticl
fairli
neg
invitro
releas
profil
nanoparticl
show
two
phase
initi
phase
burst
releas
h
follow
slow
releas
pattern
end
antimicrobi
result
reveal
nanoparticl
effect
pure
gla
p
aeuroginosa
aureu
epidermidi
improv
antibacteri
activ
gla
load
nanoparticl
compar
pure
gla
may
relat
higher
nanoparticl
penetr
infect
cell
higher
amount
gla
deliveri
site
action
herein
shown
gla
load
plga
nanoparticl
display
appropri
physicochem
properti
well
improv
antimicrobi
effect
discoveri
develop
method
target
deliveri
antibiot
infect
cell
foci
bacteri
infect
receiv
great
deal
attent
recent
year
especi
import
regard
fact
intracellular
infect
difficult
erad
infect
cell
tissu
consid
microorgan
reservoir
may
releas
time
time
result
recurr
variou
system
infect
variou
colloid
system
niosom
ethambutol
encapsul
plga
np
use
oral
mycobacterium
tuberculosi
result
show
enhanc
bioavail
improv
pharmacodynam
compar
relat
free
drug
counterpart
parenter
administr
plga
np
load
phosphorothio
antisens
oligonucleotid
nanoparticl
hiv
treatment
also
found
success
protect
oligonucleotid
degrad
antimicrobi
agent
deliveri
bacteria
np
may
base
two
differ
approach
first
approach
nanoparticl
fuse
bacteri
cell
wall
membran
carri
antimicrobi
agent
subsequ
releas
across
cell
wall
cell
membran
second
approach
nanoparticl
bound
cell
wall
serv
drug
depot
continu
releas
antimicrobi
drug
molecul
releas
antimicrobi
agent
diffus
interior
compart
bacteria
acid
gla
pentacyclictriterpenoid
deriv
betaamyrin
present
highli
pure
extract
rhizom
glycyrrhiza
glabra
glycyrrhetin
acid
rang
pharmacolog
properti
includ
calm
antiinflammatori
antiallerg
effect
well
antitumor
properti
moreov
antibacteri
antifung
activ
report
natur
occur
substanc
shown
gla
hinder
dna
replic
may
result
inhibit
microbi
toxin
enzym
product
demonstr
high
acut
exposur
gla
would
caus
brief
system
chang
includ
increas
level
potassium
excret
along
enhanc
sodium
water
retent
furthermor
follow
administr
gla
variou
side
effect
weight
gain
alkalosi
reninangiotensinaldosteron
system
suppress
hypertens
muscular
paralysi
may
occur
physic
encapsul
drug
molecul
insid
nanoparticul
system
pharmacokinet
therapeut
index
drug
significantli
improv
furthermor
lower
invivo
toxic
achiev
due
reduc
accumul
gla
kidney
liver
best
knowledg
current
liposom
microemuls
micro
nanoparticl
amongst
import
drug
deliveri
system
util
prepar
target
carrier
instanc
lutwych
et
al
achiev
higher
intracellular
antibiot
deliveri
gentamicin
encapsul
liposom
drug
deliveri
system
increas
therapeut
activ
intracellular
pathogen
achiev
effici
erad
pathogen
antibiot
abl
system
transport
form
endocytos
phagocyt
antimicrobi
agent
releas
insid
cell
respect
nanoparticl
great
valu
rapidli
pick
mononuclear
phagocyt
cell
administ
intraven
mononuclear
phagocyt
cell
kept
respons
provid
sanctuari
shelter
intracellular
bacteria
therefor
antibiot
encapsul
insid
nanoparticl
suggest
potenti
strategi
manag
variou
intracellular
infect
polymer
nanoparticl
np
sever
advantag
make
distinct
among
variou
nanoparticul
system
advantag
includ
structur
stabil
narrow
size
distribut
possibl
function
target
drug
deliveri
variou
polym
may
util
polymer
np
prepar
among
plga
poli
lacticcoglycol
acid
special
place
plga
receiv
fda
approv
biocompat
also
biodegrad
polym
commonli
use
pharmaceut
industri
research
desir
drug
carrier
advantag
plga
copolym
degrad
rate
vari
month
year
sever
report
antimicrobi
agent
load
plga
np
literatur
indic
improv
pharmacolog
pharmacokinet
behavior
compar
untreat
counterpart
plga
np
may
also
potenti
util
oral
parenter
administr
instanc
oral
administr
plga
load
curcumin
np
increas
drug
bioavail
differ
level
anoth
studi
rifampicin
isoniazid
pyrazinamid
studi
avail
formul
gla
contain
polymer
nanoparticl
intent
enhanc
gla
antibacteri
activ
aim
present
studi
develop
plga
base
nanocarri
system
gla
enhanc
antibacteri
effect
gla
minim
side
effect
develop
nanoparticl
potenti
target
infect
tissu
phagocyt
cell
exert
antibacteri
effect
variou
microorgan
staphylococcu
aureu
aureu
staphylococcu
epidermidi
epidermidi
pseudomona
aeruginosa
p
aeruginosa
chosen
model
bacteria
evalu
effect
develop
nanoparticl
microbi
organ
consid
signific
bacteria
involv
variou
infecti
diseas
human
intern
phagocyt
cell
aureu
widespread
pathogen
consid
respons
food
poison
nosocomi
infect
epidermidi
anoth
pathogen
involv
extran
devic
implant
relat
infect
due
particular
capabl
grow
biofilm
polym
surfac
p
aeruginosa
gram
neg
bacterium
anoth
common
caus
nosocomi
infect
limit
number
antibacteri
agent
show
accept
defens
organ
antimicrobi
activ
nanoparticl
compar
pure
gla
differ
gramneg
gramposit
bacteria
prepar
gla
load
plga
nanoparticl
plga
np
fabric
use
sonic
solvent
evapor
method
first
step
pva
ww
dissolv
deioniz
water
form
aqueou
phase
differ
ratio
gla
plga
dissolv
aceton
room
temperatur
prepar
organ
phase
oil
phase
prepar
oil
phase
ad
drop
wise
aqueou
phase
sonic
use
ultrason
probe
misonix
farmingdal
ny
usa
equip
microtip
power
watt
entir
system
locat
ice
bath
avoid
loss
oil
phase
result
organ
solvent
evapor
sonic
mixtur
subsequ
magnet
stir
overnight
room
temperatur
aceton
remov
constant
stir
condit
final
solut
centrifug
three
time
sigma
osterod
germani
rpm
min
order
remov
extra
pva
lyophil
christ
alpha
osterod
germani
final
dri
powder
use
physicochem
antibacteri
investig
measur
size
polydispers
index
zeta
potenti
nanoparticl
lyophil
nanoparticl
dissolv
deioniz
water
assess
photon
correl
spectroscopi
pc
use
zeta
sizer
nano
zs
malvern
instrument
worcestershir
uk
experi
accomplish
triplic
report
surfac
morpholog
shape
nanoparticl
investig
scan
electron
microscopi
sem
philip
xl
philip
netherland
small
amount
freez
dri
powder
np
fix
doublesid
tape
attach
metal
sampl
stand
gold
coat
sem
encapsul
effici
mg
lyophil
np
dispers
ml
acetonitril
shaken
second
sonic
approxim
min
ml
methanol
ad
mixtur
order
precipit
polym
sampl
centrifug
rpm
min
free
gla
contain
supernat
separ
analysi
drug
quantiti
supernat
determin
uv
spectrophotometri
method
drug
load
calcul
gla
content
np
divid
total
weight
np
encapsul
effici
obtain
calcul
ratio
gla
amount
incorpor
insid
np
gla
amount
use
np
prepar
experi
repeat
three
time
differenti
scan
calorimetri
dsc
perform
plga
gla
physic
mixtur
gla
load
plga
nanoparticl
mettler
dsc
unit
mettler
toledo
greifense
switzerland
julabo
thermocryost
model
julabo
labor
technik
seelbach
germani
indium
use
instrument
calibr
mg
sampl
place
dsc
aluminum
pan
seal
pure
water
amount
use
refer
sampl
scan
perform
temperatur
rang
rate
min
kpa
nitrogen
atmospher
drug
releas
evalu
perform
accord
previous
publish
method
piroxicam
nanoparticl
modif
mg
lyophil
gla
load
plga
np
dispers
ml
phosphat
buffer
salin
pb
place
dialysi
tube
cutoff
kda
float
flask
contain
ml
phosphat
buffer
salin
pb
medium
entir
system
locat
beaker
rpm
predetermin
period
old
medium
fulli
remov
fresh
medium
replac
time
ml
old
medium
analyz
uv
spectrophotometri
gla
content
releas
profil
free
gla
also
evalu
dialysi
bag
condit
minimum
inhibitori
concentr
mic
lowest
concentr
gla
abl
inhibit
microorgan
outgrowth
determin
gla
load
np
use
broth
micro
dilut
method
gla
np
suspens
equival
concentr
gla
base
encapsul
effici
use
aureu
epidermidi
p
aeroginosa
furthermor
drug
free
np
util
see
carrier
formul
compon
exert
antibacteri
activ
may
interfer
result
noteworthi
posit
neg
control
group
also
consid
mic
determin
studi
posit
control
group
contain
antimicrobi
agent
neg
control
group
inocul
bacteria
briefli
lyophil
bacteria
first
suspend
steril
water
inject
cultur
luria
bertuni
agar
medium
scharlau
spain
incub
h
singl
coloni
plate
transfer
ml
fluid
luria
bertuni
agar
medium
incub
rpm
shake
incub
overnight
period
next
step
centrifug
rpm
min
use
cellular
harvest
supernat
final
remov
cellular
sediment
wash
two
time
ringer
solut
dispers
medium
concentr
rang
cfuml
exploit
broth
dilut
method
sampl
bacteri
strain
eight
tube
employ
autoclav
min
sampl
serial
dilut
tube
ml
inoculum
test
bacterium
final
concentr
cfuml
introduc
tube
h
incub
tube
evalu
accord
bacteri
growth
relat
turbid
mic
determin
minimum
gla
concentr
without
visibl
bacteri
growth
prepar
character
gla
load
nanoparticl
gla
load
np
prepar
sonic
solvent
evapor
method
encapsul
effici
drug
load
size
polydispers
index
zeta
potenti
gla
load
np
report
accord
tabl
np
size
rang
nm
prepar
nanoparticl
highli
uniform
monodispers
figur
increas
drug
polym
ratio
size
increas
nm
result
may
relat
increas
viscou
forc
droplet
resist
droplet
break
sonic
especi
higher
polym
concentr
resist
forc
stand
shear
forc
oil
phase
determin
final
size
particl
size
distribut
nanoparticl
furthermor
tabl
show
increas
amount
polym
higher
encapsul
effici
achiev
maximum
encapsul
effici
attain
amount
drug
polym
ratio
observ
higher
polym
concentr
relat
higher
encapsul
effici
may
explain
two
differ
way
first
propos
polym
concentr
high
polym
molecul
may
precipit
surfac
dispers
phase
droplet
result
drug
molecul
diffus
two
phase
boundari
restrict
higher
encapsul
effici
achiev
altern
may
propos
higher
polym
concentr
increas
viscos
system
make
barrier
toward
free
diffus
drug
molecul
boundari
phase
polymer
droplet
tabl
also
show
influenc
aceton
content
size
np
ratio
continu
dispers
phase
may
effect
stabil
size
nanoparticl
shown
tabl
increas
ratio
oil
phase
size
nanoparticl
slightli
decreas
encapsul
effici
drug
load
slightli
increas
suggest
increas
ratio
aqueou
phase
extern
surfac
energi
oil
droplet
dispers
higher
volum
result
lower
droplet
breakag
subsequ
particl
size
increas
mention
gla
poorli
solubl
water
higher
affin
oil
phase
oil
water
emuls
lead
higher
entrap
effici
drug
load
increas
oil
phase
ratio
anoth
factor
evalu
effect
size
nanoparticl
sonic
time
min
result
shown
tabl
suggest
increas
sonic
time
would
result
reduct
size
nanoparticl
higher
sonic
time
min
util
high
energi
result
rapid
dispers
oil
droplet
smaller
size
monomod
profil
distribut
emulsif
step
one
vital
step
nanoparticl
format
process
inappropri
phase
dispers
result
format
larger
particl
wider
particl
size
distribut
np
size
depend
size
droplet
form
emulsif
process
result
reduc
size
emuls
droplet
smaller
nanoparticl
achiev
nanoparticl
stabil
phase
signific
step
process
emulsif
protect
nanodroplet
usual
achiev
surfact
molecul
util
surfact
molecul
prevent
occurr
coalesc
nanodroplet
produc
nanoparticl
smaller
particl
size
herein
concentr
pva
use
stabil
form
nanoparticl
develop
sort
coverag
phase
interfac
oil
water
emuls
size
zeta
potenti
anoth
major
characterist
nanoparticl
may
impact
nanoparticl
stabil
cellular
adhes
zeta
potenti
also
measur
plga
np
shown
tabl
valu
neg
zeta
potenti
nanoparticl
reduc
polym
concentr
decreas
drug
polym
ratio
reduc
neg
charg
may
attribut
higher
amount
unentrap
drug
molecul
lower
polym
concentr
shield
effect
carboxyl
moieti
plga
molecul
particl
surfac
shown
extent
phagocytosi
increas
increas
np
zeta
potenti
minimum
phagocytosi
relat
instanc
zeta
potenti
approxim
zero
hand
due
neg
surfac
charg
endotheli
cell
repuls
forc
toward
neg
charg
np
half
life
np
may
increas
blood
system
circul
keep
np
avail
phagocyt
cell
scan
electron
microscopi
sem
micrograph
gla
load
np
show
np
roughli
spheric
smooth
surfac
figur
formul
appear
monodispers
homogen
irrespect
composit
np
size
obtain
photon
correl
spectroscopi
larger
observ
sem
may
relat
hydrodynam
diamet
swollen
inflat
polymer
np
water
differenti
scan
calorimetri
dsc
use
investig
thermal
behavior
formul
figur
show
pure
plga
exhibit
endotherm
peak
relat
relax
peak
follow
glass
transit
phase
due
amorph
natur
plga
melt
point
observ
plga
thermogram
pure
gla
demonstr
sharp
peak
relat
melt
point
dsc
thermogram
physic
mixtur
gla
plga
show
peak
result
plain
superposit
two
substanc
dsc
thermogram
enthalpi
reduct
physic
mixtur
drug
polym
explain
presenc
smaller
amount
drug
molecul
mixtur
comparison
pure
drug
dsc
curv
gla
contain
np
show
endotherm
peak
gla
suggest
drug
incorpor
nanoparticl
disord
amorph
shape
sever
alter
thermal
behavior
either
polym
drug
may
relat
drug
polym
interact
current
studi
format
new
peak
shift
peak
dsc
thermogram
observ
releas
profil
pure
gla
gla
load
np
differ
drug
polym
ratio
shown
figur
time
need
dissolv
drug
invers
relat
dissolut
rate
h
h
np
drug
polym
ratio
respect
figur
also
demonstr
gla
releas
np
slower
sustain
pure
gla
drug
releas
rate
variou
drug
deliveri
system
usual
control
dissolut
andor
diffus
studi
presenc
water
insolubl
polym
np
matrix
composit
may
interfer
drug
releas
np
reduc
amount
water
penetr
np
subsequ
affect
drug
dissolut
diffus
plga
microparticl
drug
releas
usual
compos
two
phase
initi
burst
releas
follow
slower
releas
phase
burst
releas
special
import
affect
microparticl
toxic
therapeut
efficaci
burst
releas
gener
defin
total
amount
releas
drug
particul
system
first
h
total
amount
drug
releas
normal
total
drug
load
particl
present
studi
releas
profil
gla
np
formul
follow
two
phase
pattern
first
phase
initi
burst
releas
occur
take
h
follow
second
slow
releas
phase
releas
curv
demonstr
initi
burst
releas
level
depend
amount
plga
polym
np
sampl
result
show
first
h
initi
burst
releas
led
earli
releas
drug
pure
gla
gla
load
np
drug
polym
ratio
gla
load
np
drug
polym
ratio
respect
burst
releas
gla
may
relat
drug
molecul
poorli
entrap
polym
matrix
noteworthi
similar
observ
report
research
work
paclitaxel
azithromycin
plga
np
mic
gla
load
plga
np
well
free
gla
report
aureu
epidermidi
p
aeruginosa
figur
drug
free
plga
nanoparticl
display
antibacteri
effect
suggest
np
compon
ingredi
consider
antibacteri
activ
mic
gla
load
np
approxim
time
lower
aureu
time
lower
epidermidi
time
lower
p
aeroginosa
compar
free
gla
solut
regardless
drug
polym
ratio
indic
effect
dose
antibiot
reduc
administr
gla
load
plga
np
mention
bacteria
subsequ
result
lower
side
effect
consequ
invitro
antimicrobi
activ
gla
load
plga
np
better
free
drug
noteworthi
enhanc
antimicrobi
activ
antibiot
load
plga
np
previous
report
better
antibacteri
activ
may
attribut
improv
penetr
np
biolog
membran
better
access
bacteria
intern
within
phagocyt
reveal
phagocyt
cell
endocytos
np
releas
drug
insid
cell
gla
load
np
could
use
drug
target
phagocyt
cell
improv
treatment
manag
intracellular
infect
compar
free
antibiot
kind
np
success
evalu
cariou
rout
administr
includ
ocular
oral
formul
gla
load
plga
np
may
potenti
use
rout
administr
well
gla
load
plga
nanoparticl
success
prepar
appropri
size
zeta
potenti
antimicrobi
activ
evalu
show
np
effect
pure
gla
aureu
epidermidi
p
aeroginosa
propos
clinic
activ
gla
enhanc
gla
nanoparticl
formul
use
allow
effici
therapi
compar
convent
formul
free
antibiot
present
market
